December 28, 2022
1 minute read
Biomind Labs has completed development of a new sublingual formulation to be used in a Phase 2 trial of a psychedelic-based candidate for the treatment of depression and anxiety in patients with Alzheimer’s disease.
According to the company’s press release, Biomind is currently developing new pharmaceutical formulations of the psychedelic molecules 5-Metoxi-N, N-dimethyltryptamine (5-MeO-DMT), and mescaline for the treatment of a wide range of therapeutic indications. We are developing to
“Our scientific team has completed the challenging development of our proprietary sublingual formulation containing 5-MeO-DMT and manufacturing the first batch to be used in Phase 2 trials,” said CEO of Biomind. Alejandro Antaric mentioned in the release. We are very excited about the potential new drug candidates that could work on a new line of development to reduce depression and anxiety conditions in people with Alzheimer’s disease. ”
according to Paola D.Mefrom de la vallée,doctorateChief Scientific Officer at Biomind Labs, said his main goal when developing psychedelic formulations was to be convenient, cheap and painless.
“For tryptamines such as 5-MeO-DMT, they are degraded by monoamine oxidase enzymes present in the gastrointestinal tract, preventing their absorption into the circulation and central nervous system, making them neurochemically inactive when administered orally. ’” Dellavalle said in a release. “For oral administration, it will be important to add a monoamine oxidase inhibitor to protect 5-MeO-DMT from first-pass metabolism. Maximize your results.”